Article
Immunology
Riikka Viitanen, Helena Virtanen, Heidi Liljenbaeck, Olli Moisio, Xiang-Guo Li, Valeria Nicolini, Marine Richard, Christian Klein, Tapan Nayak, Sirpa Jalkanen, Anne Roivainen
Summary: In this study, the feasibility of monitoring FAP-IL2v treatment using the radiotracer [Ga-68]Ga-DOTA-Siglec-9 was evaluated. The results showed that the radiotracer could detect B16-FAP tumors and enable monitoring of FAP-IL2v treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Engineering, Biomedical
Ri Huang, Hong Du, Liang Cheng, Peizhuo Zhang, Fenghua Meng, Zhiyuan Zhong
Summary: In this study, cRGD peptide-modified bioresponsive chimaeric polymersomes (cRGD-BCP) were used for efficient delivery of siKRAS to PANC-1 tumor cells, resulting in potent silencing of KRAS G12D mRNA and effective suppression of pancreatic cancer tumor growth in mice. The density of cRGD greatly impacted the uptake and silencing efficiency of cRGD-BCP-siKRAS. cRGD-BCP-siKRAS significantly enhanced the uptake of siKRAS in PANC-1 tumor and achieved remarkable tumor inhibition and survival benefits.
ACTA BIOMATERIALIA
(2023)
Article
Pharmacology & Pharmacy
Botao Wang, Lei Yang, Tianyu Liu, Jing Xun, Yuzhen Zhuo, Lanqiu Zhang, Qi Zhang, Ximo Wang
Summary: Hydroxytyrosol (HT) inhibits the proliferation of pancreatic cancer cells and modulates the immune microenvironment, showing potential as an immunomodulatory drug for the treatment of pancreatic cancer.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Yumi Kim, Wona Jee, Eun-Jin An, Hyun Min Ko, Ji Hoon Jung, Yun-Cheol Na, Hyeung-Jin Jang
Summary: Timosaponin A3 (TA3) was found to inhibit pancreatic cancer growth through the regulation of sterol regulatory element-binding protein-1 (SREBP-1), providing a potential novel approach for the prevention and treatment of pancreatic cancer.
Article
Oncology
Dipakkumar R. Prajapati, Caitlin Molczyk, Abhilasha Purohit, Sugandha Saxena, Reegan Sturgeon, Bhavana J. Dave, Sushil Kumar, Surinder K. Batra, Rakesh K. Singh
Summary: Pancreatic cancer (PC) has a poor prognosis, and targeting CXCR2/1 using small molecule inhibitors shows promise in inhibiting PC growth, angiogenesis, and metastasis. In this study, the therapeutic utility of the CXCR2/1 antagonist SCH-479833 was evaluated in different PC murine models, demonstrating antitumor and anti-metastatic effects. CXCR2/1 antagonist treatment inhibited tumor cell proliferation, migration, angiogenesis, and neutrophil recruitment, while promoting apoptosis, fibrosis, tumor necrosis, and extramedullary hematopoiesis. These findings suggest that selectively targeting CXCR2/1 with small molecule inhibitors is a promising therapeutic approach for PC.
Review
Oncology
Fergus Keane, Catherine A. O'Connor, Wungki Park, Thomas Seufferlein, Eileen M. O'Reilly
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death in the US. PDAC with gBRCA1/2 mutations has a more favorable prognosis and additional treatment options compared to an unselected PDAC cohort. Efforts are being made to expand the use of PARP inhibitors to other genetic mutations associated with deficient DNA damage repair (DDR). Resistance to platinum-based chemotherapies and PARPi remains a challenge in improving long-term outcomes.
Article
Oncology
Yuchong Zhao, Yun Wang, Wei Chen, Shuya Bai, Wang Peng, Mengli Zheng, Yilei Yang, Bin Cheng, Zhou Luan
Summary: In pancreatic cancer, eIF4A1 downregulates E-cadherin expression through the c-MYC/miR-9 axis, promoting EMT and metastasis. Intervention on eIF4A1 and c-MYC can reduce the EMT and metastasis capabilities of pancreatic cancer cells.
CANCER CELL INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Hongjuan Yao, Wenping Song, Rui Cao, Cheng Ye, Li Zhang, Hebing Chen, Junting Wang, Yuchen Shi, Rui Li, Yi Li, Xiujun Liu, Xiaofei Zhou, Rongguang Shao, Liang Li
Summary: Chemoresistance is a main limitation for the treatment of pancreatic ductal adenocarcinoma (PDAC). Here, the authors show that an antibody drug conjugate-like compound targeting both EGFR and HER2 overcomes gemcitabine resistance in PDAC preclinical models by mechanisms involving the tumour suppressor SMAD4.
NATURE COMMUNICATIONS
(2022)
Review
Cell Biology
Hong Dai, Razack Abdullah, Xiaoqiu Wu, Fangfei Li, Yuan Ma, Aiping Lu, Ge Zhang
Summary: Pancreatic cancer is a lethal cancer with limited effectiveness of current chemotherapy. Nucleic acid-based targeting therapies have shown promising progress in the treatment of pancreatic cancer, offering potential as a future treatment direction.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Tao Wang, Ping Chen, Ruochen Dong, Scott Weir, Michael Baltezor, Frank J. Schoenen, Qi Chen
Summary: The novel compound C150 was found to inhibit epithelial-to-mesenchymal transition (EMT) in pancreatic cancer cells, leading to reduced migration and proliferation. In animal models, C150 demonstrated promising anti-tumor effects by inhibiting tumor growth and metastasis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Jingchao Li, Ningyue Yu, Dong Cui, Jiaguo Huang, Yu Luo, Kanyi Pu
Summary: This study presents the construction of semiconducting polymer pro-nanomodulators (SPpMs) for deep-tissue sono-immunotherapy of orthotopic pancreatic cancer. Through ultrasound treatment, SPpMs can generate singlet oxygen molecules to ablate tumors and release immunomodulators, enhancing antitumor immune response.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2023)
Article
Pharmacology & Pharmacy
Xuanming Liu, Hongbo Zhang, Jianlin Cao, Yuzhen Zhuo, Jiahui Jin, Qiaoying Gao, Xiangfei Yuan, Lei Yang, Dihua Li, Yan Wang
Summary: The study identified isobavachalcone (IBC) from Psoralea corylifolia L. as a valuable compound with antitumor properties that can inhibit pancreatic cancer growth by activating immune activity and inducing cell apoptosis. It was also found that IBC can regulate immune cells and suppressive cells in the tumor microenvironment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Constantin Schmitt, Dieter Saur, Stefanie Baerthel, Chiara Falcomata
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a complex disease with a heterogeneous tumor microenvironment. Mouse models, such as immunocompetent and cell line-based orthotopic allograft models, are widely used for preclinical studies. This protocol provides a reproducible and robust method for injecting PDAC cells into the mouse pancreas.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2022)
Article
Biochemistry & Molecular Biology
Wenbin Wang, Haihua Pan, Feihua Ren, Hongxia Chen, Ping Ren
Summary: This study found that ASCT2 is highly expressed in pancreatic cancer and plays a significant role in regulating glutamine metabolism and maintaining redox homeostasis. Inhibition of ASCT2 can suppress the growth of pancreatic cancer cells and induce apoptosis, suggesting ASCT2 as a potential therapeutic target for pancreatic cancer.
BIOSCIENCE REPORTS
(2022)
Article
Biotechnology & Applied Microbiology
Tao Zhang, Yu Sun, Jing Cao, Jiali Luo, Jing Wang, Zhenqi Jiang, Pintong Huang
Summary: The nucleus-targeted ultra-small Ti-TCPP MOF developed in this study represents an effective approach to enhanced SDT treatment of tumors in response to low-intensity US irradiation. This MOF showed promising therapeutic efficacy by inducing cell apoptosis and inhibiting orthotopic pancreatic tumor growth, without apparent toxicity, suggesting its potential for clinical applications.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Review
Endocrinology & Metabolism
Katharina Detjen, Linda Hammerich, Burcin Oezdirik, Munevver Demir, Bertram Wiedenmann, Frank Tacke, Henning Jann, Christoph Roderburg
Summary: GEP-NENs are rare and heterogeneous tumors originating from the endocrine system of the gastrointestinal tract and pancreas. Limited data from large prospective clinical trials are available for treatment recommendations, which are mainly based on retrospective analyses or case series. More tractable disease models are needed to better understand and predict treatment response in patients.
NEUROENDOCRINOLOGY
(2021)
Article
Gastroenterology & Hepatology
Kate Young, Rita T. Lawlor, Chanthirika Ragulan, Yatish Patil, Andrea Mafficini, Samantha Bersani, Davide Antonello, David Mansfield, Sara Cingarlini, Luca Landoni, Antonio Pea, Claudio Luchini, Liliana Piredda, Nagarajan Kannan, Gift Nyamundanda, Daniel Morganstein, Ian Chau, Bertram Wiedenmann, Michele Milella, Alan Melcher, David Cunningham, Naureen Starling, Aldo Scarpa, Anguraj Sadanandam
Summary: This study performed a comprehensive analysis of the immune landscape of PanNETs, identifying the MLP-1 subtype as an immune-high phenotype characterized by broad and robust activation of immune-related genes. The MLP-1 subtype was strongly associated with elevated levels of immune-related genes, poor prognosis, and various tumor evolutionary events, providing potential for future precision immunotherapy studies to select patients who may respond more favorably.
Article
Endocrinology & Metabolism
Bruno Niederle, Andreas Selberherr, Detlef K. Bartsch, Maria L. Brandi, Gerard M. Doherty, Massimo Falconi, Pierre Goudet, Thorvardur R. Halfdanarson, Tetsuhide Ito, Robert T. Jensen, Alberto Larghi, Lingaku Lee, Kjell Oberg, Marianne Pavel, Aurel Perren, Samira M. Sadowski, Francesco Tonelli, Frederic Triponez, Gerlof D. Valk, Dermot O'Toole, David Scott-Coombes, Rajesh V. Thakker, Geoffrey B. Thompson, Giorgio Treglia, Bertram Wiedenmann
Summary: An international consortium of experts systematically reviewed the literature on the diagnosis and treatment of DP-NENs within the MEN1 syndrome based on the highest levels of evidence, aiming to standardize and improve treatment and follow-up. The consensus statement builds upon previously published guidelines and aims to supplement recommendations from national and international societies.
NEUROENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Rodney J. Hicks, Clarisse Dromain, Wouter W. de Herder, Frederico P. Costa, Christophe M. Deroose, Andrea Frilling, Anna Koumarianou, Eric P. Krenning, Eric Raymond, Lisa Bodei, Halfdan Sorbye, Staffan Welin, Bertram Wiedenmann, Damian Wild, James R. Howe, James Yao, Dermot O'Toole, Anders Sundin, Vikas Prasad
Summary: ENETS aims to improve the standard of care for patients with neuroendocrine neoplasms (NEN) by providing standardized reporting guidance for diagnostic studies, including pathology, radiology, endoscopy, and molecular imaging. A reporting template for personalized therapies in molecular imaging procedures has been developed and is undergoing pilot implementation within the ENETS Center of Excellence network, with plans for harmonization with other specialist imaging societies.
JOURNAL OF NEUROENDOCRINOLOGY
(2022)
Article
Surgery
Federica Branchi, Rolf Klingenberg-Noftz, Kristina Friedrich, Nataly Burgel, Severin Daum, Juliane Buchkremer, Elena Sonnenberg, Michael Schumann, Christoph Treese, Hanno Troger, Donata Lissner, Hans-Jorg Epple, Britta Siegmund, Andrea Stroux, Andreas Adler, Winfried Veltzke-Schlieker, Daniel Autenrieth, Silke Leonhardt, Andreas Fischer, Christian Jurgensen, Ulrich-Frank Pape, Bertram Wiedenmann, Oliver Moschler, Maximilian Schreiner, Mathias Z. Strowski, Volkmar Hempel, Yvonne Huber, Helmut Neumann, Christian Bojarski
Summary: PuraStat gel is an effective tool for treating gastrointestinal bleeding, safely applicable as both primary and secondary therapy, and can serve as a bridge to surgery for temporary haemostasis. It shows high efficacy with low rebleeding rates.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2022)
Article
Oncology
Sachindra Sachindra, Teresa Hellberg, Samantha Exner, Sonal Prasad, Nicola Beindorff, Stephan Rogalla, Richard Kimura, Sanjiv Sam Gambhir, Bertram Wiedenmann, Carsten Groetzinger
Summary: The study evaluated a high-affinity molecular probe targeting PDAC tumors, showing promising tumor accumulation and moderate, rapidly declining kidney uptake for the tracer Lu-177-DOTA-integrin alpha v beta 6 knottin. These results support further preclinical treatment studies to establish therapeutic efficacy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
E. Merola, A. Pascher, A. Rinke, D. K. Bartsch, A. Zerbi, G. Nappo, C. Carnaghi, M. Ciola, M. G. McNamara, W. Zandee, E. Bertani, S. Marcucci, R. Modica, R. Gruetzmann, N. Fazio, W. de Herder, J. W. Valle, T. M. Gress, G. Delle Fave, G. de Pretis, A. Perren, B. Wiedenmann, M. E. Pavel
Summary: This retrospective study analyzed completely resected EP-NETs and found that approximately 30% of patients experience recurrence within 5 years after radical surgery. Through multivariable analysis, a prognostic score was determined, which includes TNM stage, lymph node ratio, margin status, and grading. The results of this study aid in identifying high-risk patients for recurrence and selecting appropriate adjuvant treatments and intensive follow-up programs.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Anja Klussmeier, Stefan Aurich, Lars Niederstadt, Bertram Wiedenmann, Carsten Groetzinger
Summary: This study demonstrates high overexpression of SCTR in esophageal and pancreatic cancer and identifies key amino acids that play a crucial role in the binding and activation of secretin with SCTR. Alterations in these structures affect their activity in cells. Future research needs to explore the application of further enhanced secretin analogues in tumor imaging and therapy.
Editorial Material
Oncology
E. Merola, A. Pascher, A. Rinke, D. K. Bartsch, A. Zerbi, G. Nappo, C. Carnaghi, M. Ciola, M. G. McNamara, W. Zandee, E. Bertani, S. Marcucci, R. Modica, R. Gruetzmann, N. Fazio, W. de Herder, J. W. Valle, T. M. Gress, G. Delle Fave, G. de Pretis, A. Perren, B. Wiedenmann, M. E. Pavel
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Elettra Merola, Aurel Perren, Anja Rinke, Alessandro Zerbi, Mairead G. McNamara, Ruza Arsenic, Nicola Fazio, Wouter de Herder, Juan W. Valle, Thomas M. Gress, Bertram Wiedenmann, Andreas Pascher, Marianne E. Pavel
Summary: The study found that in more than half of the cases with relapse after radical surgery for entero-pancreatic neuroendocrine tumors, a higher proliferative index and potentially more aggressive behavior were observed. Therefore, histological reassessment should be considered at disease recurrence to guide tailored therapeutic strategies.
JOURNAL OF NEUROENDOCRINOLOGY
(2022)
Article
Gastroenterology & Hepatology
Leonie Schuhmacher, Christian Bojarski, Victoria Reich, Andreas Adler, Winfried Veltzke-Schlieker, Christian Jurgensen, Bertran Wiedenmann, Britta Siegmund, Federika Branchi, Julianne Buchkremer, Steffen Hornoff, Dirk Hartmann, Christoph Treese
Summary: This study retrospectively compared the complication rates of the classical pull-through and direct puncture techniques for percutaneous endoscopic gastrostomy (PEG). The results showed that the direct puncture technique had a lower complication rate compared to the pull-through technique.
ENDOSCOPY INTERNATIONAL OPEN
(2022)
Article
Oncology
Raik Otto, Katharina M. Detjen, Pamela Riemer, Melanie Fattohi, Carsten Groetzinger, Guido Rindi, Bertram Wiedenmann, Christine Sers, Ulf Leser
Summary: Machine learning approaches can improve the classification accuracy of neuroendocrine neoplasms (NEN), but usually require large amounts of training data. This study used machine learning-aided classification based on the similarity between NEN and non-transformed pancreatic cell types to predict patient survival time, neoplastic grading, and carcinoma versus tumor subclassification, providing additional criteria for confident classification of ambiguous cases.
Article
Oncology
Wiebke Werner, Katharina Detjen, Alix Bruneau, Isabella Lurje, Natalie Nestel, Henning Jann, Frank Tacke, Bertram Wiedenmann, Christoph Roderburg, Linda Hammerich
Summary: In a retrospective study on neuroendocrine tumors, the levels of FLT3LG mRNA were found to be correlated with the abundance of immune cells cDC and T cells, which also predicted disease-specific survival. The combination of FLT3LG and T cell counts improved this prediction, suggesting their potential as prognostic markers.
ENDOCRINE-RELATED CANCER
(2023)
Article
Oncology
Evelyn Kidess, Yvonne Giesecke, Ines Eichhorn, Raphael Mohr, Henning Jann, Christian Fischer, Bertram Wiedenmann, Christoph Roderburg, Frank Tacke, Michael Sigal
Summary: The study aimed to analyze plasma concentrations of OPN in patients with NEN and explore its diagnostic and prognostic value. The results showed that OPN levels were significantly higher in NEN patients compared to healthy controls, with the highest levels in high-grade tumors (grade 3). In addition, patients with initial OPN levels above 200 ng/ml had a poor prognosis in terms of shorter progression-free survival, both in the overall NEN patient group and within the subgroup of well-differentiated G1/G2 tumors. Therefore, OPN can serve as a surrogate prognostic biomarker in NEN patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Frederico Costa, Bertram Wiedenmann, Christoph Roderburg, Raphael Mohr, Ghassan K. Abou-Alfa
Summary: Hepatocellular carcinoma (HCC) is a leading cause of death in liver cirrhosis patients. Immuno-oncology has revolutionized the treatment for advanced HCC, but most trials exclude patients with moderate liver dysfunction. Patients with HCC and moderate liver dysfunction have a low overall survival rate with sorafenib treatment, indicating the need for improved treatment strategies.